The multicomponent medication Spascupreel attenuates stress‐induced gut dysfunction in rats
Background Irritable bowel syndrome (IBS) is a common disorder worldwide. It is characterized by abdominal pain/discomfort and changes in bowel habits. Due to the multifactorial pathophysiology and the heterogeneity of IBS patients, appropriate treatment of IBS is still a challenge. Spascupreel (SP‐...
Gespeichert in:
Veröffentlicht in: | Journal of neurogastroenterology and motility 2020-05, Vol.32 (5), p.e13798-n/a |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Irritable bowel syndrome (IBS) is a common disorder worldwide. It is characterized by abdominal pain/discomfort and changes in bowel habits. Due to the multifactorial pathophysiology and the heterogeneity of IBS patients, appropriate treatment of IBS is still a challenge. Spascupreel (SP‐11), as a multicomponent medication, has the potential to modulate multiple pathophysiological pathways simultaneously. Therefore, the objective of the current study was to investigate the effects of oral SP‐11 treatment on stress‐induced changes of peripheral and central functions in a rat model mimicking human IBS.
Methods
Naïve Wistar rats were treated with SP‐11 (0.9 tab/kg) or NaCl 0.9% by oral gavage for 4 days before 2‐hour partial restraint stress (PRS) procedure. Twenty minutes after PRS, central and peripheral stress‐induced changes affecting IBS were assessed. These include the hypothalamic‐pituitary‐adrenal (HPA) axis response through plasma ACTH and corticosterone measurements, visceral pain in response to colorectal distension, gut permeability, colonic mast cell number, and sensitization as well as gut transit time.
Results
Treatment with SP‐11 reduced the HPA axis activation in response to PRS. At the gut level, a reduction in colonic hypersensitivity to colorectal distension, a normalization of gut transit time acceleration, a reduced mast cell sensitization, and a trend toward reduced gut hyperpermeability were observed.
Conclusions
These data suggest that stress‐induced IBS signs can be reduced using SP‐11 in rats. The observed effects and the good tolerability of the drug make SP‐11 an innovative candidate in the management of IBS.
In a stress‐induced rat model of irritable bowel syndrome (IBS), SP‐11 reduced the hypothalamic‐pituitary‐adrenal axis activation and positively modulated the gut function. Multiple pathophysiological pathways were beneficially targeted by SP‐11 leading to a reduction of IBS signs in rats. |
---|---|
ISSN: | 1350-1925 2093-0879 1365-2982 2093-0887 |
DOI: | 10.1111/nmo.13798 |